{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:56:30Z","timestamp":1790596590804,"version":"4.1.0"},"reference-count":16,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,4,14]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Maintenance and reliever therapy (MART) with budesonide\/formoterol (BUD\/FORM) may offer asthma control with a single inhaler. This 6-month exploratory study monitored asthma symptoms, reliever use, lung function, airway inflammation and exacerbation events to determine treatment effectiveness in patients receiving BUD\/FORM MART or BUD\/FORM maintenance therapy plus short-acting \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -agonist (SABA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In the open-label STIFLE study (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03924635\">NCT03924635<\/jats:ext-link>\n                      ), patients were randomised to BUD\/FORM MART (100\u2005\u03bcg\/6\u2005\u03bcg or 200\u2005\u03bcg\/6\u2005\u03bcg per inhalation,\n                      <jats:italic>pro re nata<\/jats:italic>\n                      (PRN)) or the same dose of BUD\/FORM BID as maintenance therapy plus SABA (salbutamol) reliever PRN (100\u2005\u03bcg per inhalation). Data were captured at home each day using devices connected to a smartphone\n                      <jats:italic>via<\/jats:italic>\n                      the STIFLE application. Occurrence of pre-defined exacerbation events required patients to attend hospital for assessment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      42 patients were randomised. Adherence to daily measurements exceeded 80% in both treatment groups. The proportion of patients experiencing an exacerbation was 27.8% in the BUD\/FORM MART\n                      <jats:italic>versus<\/jats:italic>\n                      70.8% in the BUD\/FORM maintenance plus SABA group. A similar trend was observed in patients who experienced \u22651\u2005day with \u22656 reliever uses (3 (16.7%)\n                      <jats:italic>versus<\/jats:italic>\n                      9 (37.5%) patients, respectively). Patients treated with BUD\/FORM MART showed less variation in airway inflammation, asthma symptom scores, lung function parameters and reliever use,\n                      <jats:italic>versus<\/jats:italic>\n                      BUD\/FORM maintenance therapy plus SABA. No unexpected safety findings were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with moderate asthma treated with BUD\/FORM MART recorded less variation in asthma outcomes and lower rates of exacerbation events than those treated with BUD\/FORM maintenance therapy plus SABA, suggesting improved asthma control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00116-2026","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:40:34Z","timestamp":1782952834000},"page":"00116-2026","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Airway inflammation and asthma control in patients using salbutamol or budesonide\/formoterol reliever: a randomised, controlled study"],"prefix":"10.1183","volume":"12","author":[{"given":"Matthew J.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Saralaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay G.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Belton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Rutgersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vieshal","family":"Raja Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026092804100807000_12.5.00116-2026.1","unstructured":"World Health Organization . Asthma. Date last updated: 28 April 2026. Date last accessed: 9 July 2026. www.who.int\/news-room\/fact-sheets\/detail\/asthma"},{"key":"2026092804100807000_12.5.00116-2026.2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12931-023-02475-6","article-title":"Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"24","author":"Wang","year":"2023","journal-title":"Respir Res"},{"key":"2026092804100807000_12.5.00116-2026.3","doi-asserted-by":"crossref","first-page":"103051","DOI":"10.1016\/j.eclinm.2024.103051","article-title":"Global, regional, national burden of asthma from 1990 to 2021, with projections of incidence to 2050: a systematic analysis of the global burden of disease study 2021","volume":"80","author":"Yuan","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026092804100807000_12.5.00116-2026.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.01971.x"},{"key":"2026092804100807000_12.5.00116-2026.5","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01233-0"},{"key":"2026092804100807000_12.5.00116-2026.6","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/jcm9040921","article-title":"Effective asthma management: is it time to let the AIR out of SABA?","volume":"9","author":"Kaplan","year":"2020","journal-title":"J Clin Med"},{"key":"2026092804100807000_12.5.00116-2026.7","doi-asserted-by":"crossref","first-page":"00140\u20132022","DOI":"10.1183\/23120541.00140-2022","article-title":"SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada)","volume":"8","author":"Noorduyn","year":"2022","journal-title":"ERJ Open Res"},{"key":"2026092804100807000_12.5.00116-2026.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01872-2019"},{"key":"2026092804100807000_12.5.00116-2026.9","unstructured":"Royal College of Physicians. Why asthma still kills. Date last updated: 18 July 2016. Date last accessed: 9 July 2026. www.rcp.ac.uk\/resources\/why-asthma-still-kills\/"},{"key":"2026092804100807000_12.5.00116-2026.10","doi-asserted-by":"crossref","first-page":"00333\u20132019","DOI":"10.1183\/23120541.00333-2019","article-title":"Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design","volume":"6","author":"Harrison","year":"2020","journal-title":"ERJ Open Res"},{"key":"2026092804100807000_12.5.00116-2026.11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.anai.2020.04.009","article-title":"Asthma maintenance and reliever therapy: should this be the standard of care?","volume":"125","author":"Cusack","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026092804100807000_12.5.00116-2026.12","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-13-59"},{"key":"2026092804100807000_12.5.00116-2026.13","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.056093"},{"key":"2026092804100807000_12.5.00116-2026.14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-2600(17)30218-7","article-title":"A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials","volume":"5","author":"Fuhlbrigge","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026092804100807000_12.5.00116-2026.15","unstructured":"Global Initiative for Asthma . Global strategy for asthma management and prevention. Date last updated: 2018. Date last accessed: 9 July 2026. https:\/\/ginasthma.org\/wp-content\/uploads\/2018\/04\/wms-GINA-2018-report-V1.3-002.pdf"},{"key":"2026092804100807000_12.5.00116-2026.16","unstructured":"Global Initiative for Asthma . Global strategy for asthma management and prevention. Date last updated: 2024. Date last accessed: 9 July 2026. https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00116-2026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:10:18Z","timestamp":1790593818000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00116-2026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,28]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1183\/23120541.00116-2026"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00116-2026","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}